05/04/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/4/2020. This 41-page guidance, updated on May 4, 2020, provides a policy to help accelerate the availability of novel coronavirus (COVID-19) tests developed by laboratories and commercial manufacturers for the duration of the public health emergency. (PDF)
05/04/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/4/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG), which received an Emergency Use Authorization from the Food and Drug Administration on May 4, 2020. The EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG) is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (K+-EDTA, Li+-heparin, Na+-citrate). (PDF)
05/04/2020 12:00 AM EDT
Source: Imperial College London. Published: 5/4/2020. This 35-page report summarizes analysis that modeled the effect of non-pharmaceutical interventions on COVID-19 transmission using data on average mobility in Italy. It estimates that the average reproduction number (a measure of transmission intensity) is currently below one for all Italian regions, and significantly so for the majority of the regions. (PDF)
05/04/2020 12:00 AM EDT
Source: RAND Corporation. Published: 5/4/2020. This 96-page document describes the interdisciplinary and multisectoral approach RAND researchers used to develop the COVID-19 Decision Support Tool, which is designed to fill the need for a comprehensive and systematic assessment of potential public health interventions to address COVID-19 and when to relax them. (PDF)
05/03/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/3/2020. This guidance, updated on May 3, 2020, is for healthcare providers and public health officials managing persons with coronavirus disease 2019 (COVID-19) under isolation who are not in healthcare settings. This includes, but is not limited to, at home, in a hotel or dormitory room, or in a group isolation facility. (Text)
05/03/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/3/2020. This guidance, updated on May 3, 2020, details how in the context of COVID-19 community transmission where continued testing is impractical, available evidence at this time indicates that an interim strategy based on time-since-illness-onset and time-since-recovery can be implemented to establish the end of isolation. (Text)
05/02/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/2/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Elecsys Anti- SARS-CoV-2 immunoassay, which received an Emergency Use Authorization from the Food and Drug Administration on May 2, 2020. The Elecsys Anti-SARS-CoV-2 immunoassay is authorized for the detection of antibodies to SARS-CoV-2 in human serum or plasma. (PDF)
05/01/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/1/2020. This two-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a protective barrier enclosure during the COVID-19 pandemic. The virus that causes COVID-19 is highly contagious, and the protective barrier enclosure provides an additional layer of protection when exposure to bodily fluids and airborne particles or droplets from COVID-19 patients are expected. (PDF)
05/01/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/1/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Bio-Rad SARS-CoV-2 ddPCR Test, which received an Emergency Use Authorization from the Food and Drug Administration on May 1, 2020. The Bio-Rad SARS-CoV-2 ddPCR Testis authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/01/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/1/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BioFire® Respiratory Panel 2.1 (RP2.1), which received an Emergency Use Authorization from the Food and Drug Administration on May 1, 2020. The BioFire® RP2.1 test is authorized for use on using respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
05/01/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/1/2020. This two-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the VentFree Respiratory Muscle Stimulator, which received an Emergency Use Authorization from the Food and Drug Administration on May 1, 2020, in healthcare settings for treatment of mechanically ventilated adult patients during the COVID-19 pandemic. (PDF)
05/01/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/1/2020. Based on the experiences of healthcare systems as they respond to COVID-19, this guidance provides 10 practical approaches that can be used to protect healthcare personnel (HCP), patients, and communities, and operate effectively during the pandemic. (Text)
05/01/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 5/1/2020. The purpose of this four-page paper is to support pharmacists and other staff working in community pharmacies with guidance on the issues raised by the COVID-19 outbreak. It supports the operationalization of the policy recommendations for the World Health Organization European Region on strengthening the health system response to COVID-19. (PDF)
04/30/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/30/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the New York SARS-CoV Microsphere Immunoassay for Antibody Detection test, which received an Emergency Use Authorization from the Food and Drug Administration on April 30, 2020. The New York SARS-CoV Microsphere Immunoassay for Antibody Detection test is authorized for the detection of total antibody (IgG, IgM, and IgA) to SARS-CoV-2 in human serum. (PDF)
04/30/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/30/2020. This two-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Fresenius multiFiltrate PRO System and multiBic/multiPlus Solutions to provide continuous renal replacement therapy to treat patients in an acute care environment during the COVID-19 pandemic. (PDF)
04/30/2020 12:00 AM EDT
Source: Center for Infectious Disease Research and Policy [University of Minnesota] (CIDRAP). Published: 4/30/2020. This nine-page report discusses how we can potentially learn from past influenza pandemics as we attempt to determine a vision for the future of the COVID-19 pandemic. Identifying key similarities and differences in the epidemiology of COVID-19 and pandemic influenza can help envisioning several possible scenarios for the course of the COVID-19 pandemic. (PDF)
04/30/2020 12:00 AM EDT
Source: Henry J. Kaiser Family Foundation. Published: 4/30/2020. This analysis compares COVID-19 cases and deaths in metropolitan and non-metropolitan counties in the United States. It finds that while metro counties still have significantly higher cases and deaths per capita, non-metro counties are experiencing faster growth rates, potentially signaling challenges ahead. (Text)
04/28/2020 12:00 AM EDT
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 4/28/2020. This seven-page document from TRACIE (Technical Resources, Assistance Center, and Information Exchange) provides an overview of recommendations and resources for nursing homes that can help reduce the impact of COVID-19 on residents and staff. Sections discuss Overview of COVID-19; Prevention, detection, and control; Interface with hospitals and other healthcare facilities; and Personal protective equipment inventory management. (PDF)
04/28/2020 12:00 AM EDT
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 4/28/2020. This nine-minute video from TRACIE (Technical Resources, Assistance Center, and Information Exchange) can help healthcare providers create self-care plans to minimize stress and boost resilience during the COVID-19 pandemic. (Video or Multimedia)
04/25/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 4/25/2020. This web page, updated on April 25, 2020, discusses how there are no Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present, clinical management includes infection prevention and control measures and supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. It provides links to National Institutes of Health guidance and information about clinical trials. (Text)
04/09/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 4/9/2020. This eight-page document summarizes current World Health Organization (WHO) recommendations for the treatment of COVID-19 patients, information on the ethical and legal requirements for the use of experimental medicines in clinical trials (the WHO SOLIDARITY trial or other Randomized Control Trials) as well as donated medicines, and the possible impact on global supplies of essential medicines for the treatment of non-COVID-19 patients where these drugs are included in COVID-19 clinical trials. (PDF)
04/06/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 4/6/2020. This 18-page document is for decision-makers, policymakers, and national or regional health authorities tasked with creating surge capacity in acute and intensive care to treat COVID-19 patients while maintaining essential hospital services. More specifically, it organizes guidance around the four components of surge capacity: space, staff, supplies, and systems, and stresses the need for a comprehensive approach that links the four together. (PDF)
04/06/2020 12:00 AM EDT
Source: World Health Organization, Regional Office for Europe. Published: 4/6/2020. The purpose of this eight-page paper is to provide World Health Organization Regional Office for Europe Country Offices and Member States with guidance on how to maintain supplies of medicines and health technologies, including devices, diagnostics, and blood products, during the COVID-19 outbreak. (PDF)
04/01/2020 12:00 AM EDT
Source: National Center for PTSD [Post-Traumatic Stress Disorder] [U.S. Department of Veterans Affairs]. Published: 4/2020. This app was created for everyone, including veterans and service members, to support self-care and overall mental health during the coronavirus (COVID-19) pandemic. Features include education about coping during the pandemic, tools for self-care and to improve emotional well-being, trackers to check your mood and measure your growth toward personal goals, and graphs to visualize progress over time. (Video or Multimedia)
.png)
No hay comentarios:
Publicar un comentario